INDBInternet News Database 2.5 Updated 1 min ago · 316 sources Show or hide images Light or dark

Benmelstobart Extends PFS After Chemoradiotherapy in NSCLC

Save Like Comments Compare coverage

Summary

Researchers evaluate benmelstobart, with or without anlotinib, for use as consolidation therapy after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    Benmelstobart Extends PFS After Chemoradiotherapy in NSCLC

    Researchers evaluate benmelstobart, with or without anlotinib, for use as consolidation therapy after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.

Comments

Comments need JavaScript.